THERAPEUTIC HORIZONS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE( MASLD) & METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS( MASH): A SYSTEMATIC REVIEW OF CURRENT TREATMENT OPTION

被引：0
|
作者：
Moliya, Pratiksha [1 ]
Al-Obaidi, Hasan [1 ]
Patel, Pranav [2 ]
Patel, Raj
Parikh, Charmy [3 ]
Joy, Melvin [4 ]
机构：
[1] Jama Hosp Med Ctr, Jamaica, NY USA
[2] Geisinger Med Ctr, Danville, PA USA
[3] Mercy Catholic Med Ctr, Darby, PA USA
[4] Nassau Univ Med Ctr, East Meadow, NY USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1614
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [2] DEGREE OF METABOLIC DYSFUNCTION IS LINKED TO STEATOHEPATITIS (MASH), FIBROSIS, AND HIGHER CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Kim, David
    Abboud, Yazan
    Ismail, Mohamed
    Goyal, Ritik Mahaveer
    Pyrsopoulos, Nikolaos
    Kim, Hyunseok
    Hajifathalian, Kaveh
    Al-Khazraji, Ahmed
    HEPATOLOGY, 2024, 80 : S441 - S442
  • [3] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [4] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [5] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [6] Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
    Younossi, Zobair M.
    Razavi, Homie
    Sherman, Michael
    Allen, Alina M.
    Anstee, Quentin M.
    Cusi, Kenneth
    Friedman, Scott L.
    Lawitz, Eric
    Lazarus, Jeffrey V.
    Schuppan, Detlef
    Romero-Gomez, Manuel
    Schattenberg, Joern M.
    Vos, Miriam B.
    Wong, Vincent Wai-Sun
    Ratziu, Vlad
    Hompesch, Marcus
    Sanyal, Arun J.
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025,
  • [7] Evaluation of liver fibrosis and steatohepatitis associated with metabolic dysfunction (MASH) in patients with inflammatory bowel disease (IBD) and steatotic liver disease associated with metabolic dysfunction (MASLD)
    Oliveira, E. C. S. D.
    Lopes, M. A.
    Beraldo, R. F.
    Castelhano, N. S.
    Baima, J. P.
    Herrerias, G. S. P.
    Quaglio, A. E., V
    Di Stasi, L. C.
    Barbosa, W. F.
    Silva, G. F.
    Sassaki, L. Y.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i666 - i666
  • [8] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Do, Albert
    Zahrawi, Frhaan
    Mehal, Wajahat Z.
    NATURE REVIEWS DRUG DISCOVERY, 2024,
  • [9] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Do, Albert
    Zahrawi, Frhaan
    Mehal, Wajahat Z.
    NATURE REVIEWS DRUG DISCOVERY, 2025, 24 (03) : 171 - 189
  • [10] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Albert Do
    Frhaan Zahrawi
    Wajahat Z. Mehal
    Nature Reviews Drug Discovery, 2025, 24 (3) : 171 - 189
12345